Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine

References

• ShomaliMAdd-on therapies to metformin for type 2 diabetesExpert Opin Pharmacother2011121476221142694
   PubMed Web of Science ®Google Scholar
• WrightABurdenACPaiseyRBCullCAHolmanRRSulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57)Diabetes Care200225233033611815505
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia20125561577159622526604
   PubMed Web of Science ®Google Scholar
• American Diabetes Association (ADA)Standards of medical care in diabetes – 2012Diabetes Care201235Suppl 1S11S6322187469
   PubMed Web of Science ®Google Scholar
• OwensDRLuzioSDSert-LangeronCRiddleMCEffects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ studyDiabetes Obes Metab201113111020102721679291
   PubMed Web of Science ®Google Scholar
• RaskinPAllenEHollanderPInitiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogsDiabetes Care200528226026515677776
   PubMed Web of Science ®Google Scholar
• RaskinPRHollanderPALewinAGabbayRABodeBGarberAJBasal insulin or premix analogue therapy in type 2 diabetes patientsEur J Intern Med2007181566217223044
   PubMed Web of Science ®Google Scholar
• BoyeKSMatzaLSWalterKNVan BruntKPalsgroveACTynanAUtilities and disutilities for attributes of injectable treatments for type 2 diabetesEur J Health Econ201112321923020224930
   PubMed Web of Science ®Google Scholar
• PeyrotMRubinRRPolonskyWHBestJHPatient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogsCurr Med Res Opin20102651047105420199136
   PubMed Web of Science ®Google Scholar
• FritscheALarbigMOwensDHäringHUComparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER studyDiabetes Obes Metab201012211512320092584
   PubMed Web of Science ®Google Scholar
• HolmanRRThorneKIFarmerAJAddition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetesN Engl J Med2007357171716173017890232
   PubMed Web of Science ®Google Scholar
• HolmanRRFarmerAJDaviesMJThree-year efficacy of complex insulin regimens in type 2 diabetesN Engl J Med2009361181736174719850703
   PubMed Web of Science ®Google Scholar
• SchielRMüllerUAEfficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot StudyExp Clin Endocrinol Diabetes20081161586417973208
   PubMed Web of Science ®Google Scholar
• ReaneyMCyprykKTentolourisNResource utilisation and clinical data before and after switching between short-acting human insulin and rapid-acting insulin analogues in patients with type 2 diabetes: the SWING studyDiabetes Res Clin Pract201297223124122483577
   PubMed Web of Science ®Google Scholar
• DaviesMSinnassamyPStormsFGomisRInsulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapiesDiabetes Res Clin Pract200879236837517980928
   PubMed Web of Science ®Google Scholar
• LakeyWCBarnardKBatchBCChiswellKTasneemAGreenJBAre current clinical trials in diabetes addressing important issues in diabetes care?Diabetologia20135661226123523564296
   PubMed Web of Science ®Google Scholar
• ConcatoJShahNHorwitzRIRandomized, controlled trials, observational studies, and the hierarchy of research designsN Engl J Med2000342251887189210861325
   PubMed Web of Science ®Google Scholar
• HammerHKlingeAPatients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practiceInt J Clin Pract200761122009201817997807
   PubMed Web of Science ®Google Scholar
• SharplinPGordonJPetersJRTetlowAPLongmanAJMcEwanPSwitching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysisCardiovasc Diabetol20098919220880
   PubMed Web of Science ®Google Scholar
• BlakBTSmithHTHardsMCurtisBHIvanyiTOptimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulinDiabet Med2012297e13e2022268988
   PubMed Web of Science ®Google Scholar
• BaserOBouchardJDeLuzioTHenkHAagrenMAssessment of adherence and healthcare costs costs of insulin device (FlexPen®) versus conventional vial/syringeAdv Ther20102729410420352392
   PubMed Web of Science ®Google Scholar
• National Committee for Quality AssuranceHEDIS 2013 Available from: http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS2013.aspxAccessed July 19, 2013
   Google Scholar
• ChenGKhanNWalkerRQuanHValidating ICD coding algorithms for diabetes mellitus from administrative dataDiabetes Res Clin Pract201089218919520363043
   PubMed Web of Science ®Google Scholar
• DavisSNWeiWGargSClinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care settingEndocr Pract201117684585221550952
   PubMed Web of Science ®Google Scholar
• XieLZhouSWeiWGillJPanCBaserODoes pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitusDiabetes Technol Ther201315323023623336845
   PubMed Web of Science ®Google Scholar
• XieLWeiWPanCDuJBaserOA real-world study of patients with type 2 diabetes initiating basal insulins via disposable pensAdv Ther201128111000101122038703
   PubMed Web of Science ®Google Scholar
• BaserOWeiWBaserEXieLClinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BIDJ Med Econ201114667368021892858
   PubMedGoogle Scholar
• LevinPWeiWWangLPanCDouglasDBaserOCombination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetesCurr Med Res Opin201228343944622216894
   PubMed Web of Science ®Google Scholar
• ZhaoYCampbellCRFonsecaVShiLImpact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetesDiabetes Care20123551126113222432106
   PubMed Web of Science ®Google Scholar
• RosenbaumPRRubinDBThe central role of the propensity score in observational studies for causal effectsBiometrika19837014155
   Web of Science ®Google Scholar
• CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
   PubMed Web of Science ®Google Scholar
• PolonskyWHRosenstockJGilmoreASWeiWChaudhsSLRiddleMCPatient reported outcomes using twice-daily insulin aspart premixed vs insulin glargine plus 1 prandial insulin glulisine or step-wise addition of glulisine to glargine in type 2 diabetes uncontrolled with oral agents [abstract]Diabetes201160Suppl 1A616
   Google Scholar
• GordonJPockettRDTetlowAPMcEwanPHomePDA comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database studyInt J Clin Pract201064121609161820946269
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and QualityComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults with Type 2 Diabetes: Executive SummaryRockville (MD)AHRQ2008 Available from: http://effectivehealthcare.ahrq.gov/ehc/products/18/108/2008_0915InsulinAnaloguesExecSum.pdfAccessed July 19, 2013
   Google Scholar
• IlagLLKerrLMaloneJKTanMHPrandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparisonClin Ther2007296 Pt 112541270
   Web of Science ®Google Scholar